会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 58. 发明授权
    • Reversal of proinflammatory response by ligating the macrophage Fc&ggr;RI receptor
    • 通过连接巨噬细胞FcgammaRI受体逆转促炎反应
    • US06660266B1
    • 2003-12-09
    • US09692586
    • 2000-10-19
    • David M. MosserFayyaz Sutterwala
    • David M. MosserFayyaz Sutterwala
    • A61K39395
    • C07K16/1203A61K38/00A61K2039/505C07K16/1242C07K16/28C07K16/2806C07K2317/52
    • Ligation of the Fc&ggr; receptor type I (Fc&ggr;RI) on IL-10-producing cells leads to a selective upregulation of IL-10 production, which in turn induces a marked suppression of IL-12 biosynthesis by IL-12-producing cells, particularly macrophages. The ligation of the Fc&ggr;RI receptor thus downmodulates IL-12 production via a mechanism that is dependent on macrophage-derived IL-10. Agents for ligating Fc&ggr;RI comprise, for example, multivalent antibodies which bind the Fc&ggr;RI receptor, immune complexes comprising antibodies which contain the Fc region of IgG, and IgG multimers, preferably IgG dimers and trimers. The ligating agent may be administered to therapeutically inhibit proinflammatory immune responses. In particular, the ligating agent may be administered to treat or prevent endotoxic shock associated with bacterial endotoxemia, and to treating autoimmune disorders.
    • 在产生IL-10的细胞上的Fcgamma受体I型(FcgammaRI)的连接导致IL-10产生的选择性上调,这又导致IL-12生产细胞,特别是巨噬细胞对IL-12生物合成的显着抑制 。 Fcgamma受体的连接因此通过依赖于巨噬细胞衍生的IL-10的机制来下调IL-12的产生。 用于连接FcγRRI的药剂包含例如结合FcγR受体的多价抗体,包含含有IgG的Fc区的抗体的免疫复合物和IgG多聚体,优选IgG二聚体和三聚体。 可以施用连接剂以治疗性地抑制促炎免疫应答。 特别地,可以施用连接剂以治疗或预防与细菌内毒素血症相关的内毒素性休克,以及治疗自身免疫性疾病。